Clinical trials: Tace
Hepatocellular Carcinoma
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or…
- Trial name
- CCGLC-004 (NCT05103007)
- Testing
- DEB-TACE, PVL/PVE+DEB-TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma, TACE
Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
A single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC) patients at high risk of post…
- Conditions
- Hepatocellular Carcinoma, TACE, Anlotinib
- Trial name
- ALTER-H-004 (NCT04213118)
- Testing
- Anlotinib Hydrochloride, TACE
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Liver Cancer
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for…
- Trial name
- NCT02646137
- Testing
- Transarterial chemoembolization (TACE), Radiofrequency ablation combined with TACE, Microwave ablation combined with TACE
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sherief Abd-Elsalam
Hepatocellular Carcinoma
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
The investigators design a phase II clinical study to explore the efficacy and safety of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with Unresectable, non-metastatic hepatocellular…
- Trial name
- NCT05903456
- Testing
- TACE（transcatheter arterial chemoembolization）, lenvatinib, Icaritin soft capsules
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, Hepatocellular Cancer
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable hepatocellular carcinoma that has not responded to transarterial chemoembolization.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
- Trial name
- NCT01618253
- Testing
- Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Hepatocellular Carcinoma
BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.
The primary objective of the study is to confirm safety and efficacy of BioPearl™ microspheres loaded with doxorubicin in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-FIRST (NCT04231929)
- Testing
- Chemoembolization
- Where
- 3 sites in Belgium
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma (HCC), CT
CT Volume Measurement of Hepatocellular Carcinoma
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
- Trial name
- NCT07183566
- Testing
- Ct
- Volunteers
- 66 people
- Sponsor
- Assiut University
Early Hepatocellular Carcinoma
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use…
- Trial name
- SOCRATES HCC (NCT07628751)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR), Therapies
- Where
- 2 sites in Australia, Canada
- Volunteers
- 218 people
- Sponsor
- University Health Network, Toronto
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
- Trial name
- NCT03608878
- Testing
- adagloxad simolenin/OBI-821, TACE
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) as the third most common cause of cancer-related death has a very poor prognosis. Aim of this open label single arm non randomized pilot trial is the evaluation of the efficacy and safety of…
- Trial name
- NCT00768937
- Testing
- Sorafenib, Transarterial chemoembolisation (TACE)
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Medical University of Vienna
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma Non-resectable
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
- Trial name
- NCT05985798
- Testing
- Sin-Bev-TACE, Len-TACE
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic…
- Trial name
- BIIRTH (NCT07293468)
- Testing
- Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- Tuen Mun Hospital
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
- Trial name
- NCT04297280
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial chemoembolization (TACE) or transarterial radioembolization…
- Trial name
- REPLACE (NCT04777851)
- Testing
- Regorafenib in combination with pembrolizumab, Loco-regional therapy
- Where
- 26 sites in United States, Belgium and 11 more
- Volunteers
- 45 people
- Sponsor
- Translational Research in Oncology
Hepatocellular Carcinoma
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to…
- Trial name
- HiQuality (NCT01387932)
- Testing
- HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 235 people
- Sponsor
- Merit Medical Systems, Inc.
Hepatocellular Carcinoma
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients…
- Trial name
- NCT04174781
- Testing
- Sintilimab, DEB-TACE
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University